Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
11:00am, Friday, 18'th Jul 2025
Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
06:00am, Thursday, 17'th Jul 2025
VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
01:00pm, Friday, 20'th Jun 2025
Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
04:34pm, Thursday, 12'th Jun 2025
Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Ph
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
11:01am, Wednesday, 04'th Jun 2025
The consensus price target hints at a 76.7% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
05:00pm, Thursday, 22'nd May 2025
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 21'st May 2025
VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
04:15pm, Monday, 19'th May 2025
VANCOUVER, British Columbia, May 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
11:01am, Wednesday, 14'th May 2025
The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
11:00pm, Thursday, 08'th May 2025
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Senior Director, Investor Relations Ken Galbraith - Chair & CEO Paul Moore
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
06:56pm, Thursday, 08'th May 2025
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.42 per share a year ago.
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 08'th May 2025
VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline
05:33pm, Monday, 28'th Apr 2025
Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER
Zymeworks: Poised For Growth With Platform Validation
10:48am, Monday, 28'th Apr 2025
Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3
